Become A Featured Company

Marijuana Breathalyzer Moves Closer to Reality

Ryan Allway

November 16th, 2016

News, Top News

The November elections expanded cannabis access to more than a quarter of the United States population, with voters in California, Nevada, and Massachusetts endorsing recreational marijuana use in statewide votes. At the same time, Canadian Prime Minister Justin Trudeau is in the process drafting recreational marijuana laws to supplement the country’s existing nationwide medical marijuana regulatory framework.

Law enforcement officials have expressed growing concern over these trends. A review of 60 studies presented in 1995 at the International Conference on Alcohol, Drugs, and Traffic Safety found that marijuana impairs all the cognitive abilities needed for safe driving, including tracking, motor coordination, visual function, and divided attention. The problem is that roadside detection of THC has been an elusive technology to master.

Developing a Breathalyzer

The most effective roadside detection device would be a breathalyzer, since it is easy to administer and delivers instant results. It is well documented that there is currently no marijuana breathalyzer available for wide use as of yet. Cannabix Technologies Inc. (OTC: BLOZF) of Vancouver, BC has been working on developing a marijuana breathalyzer that would be used as a point of care device. Its patent pending breathalyzer uses FAIMS (high-field asymmetric waveform ion mobility spectrometry) technology (in collaboration with the University of Florida) to achieve a highly sensitive device that would be capable of detecting THC in breath.

cannabix-beta1

On November 11, the company released images of its Beta 2.0 Cannabix Marijuana Breathalyzer and provided a progress update. The new prototype includes a robust detection system and components platform that will be used in an eventual finalized product. The prototype has provided excellent sensitivity in lab testing and will be utilized to conduct scientific studies with live marijuana users to test for accuracy and sensitivity.

Rigorous Scientific Testing

There are many potential problems with assessing the impairment of high drivers. For example, Colorado relies on blood tests and a 5 nanogram THC limit when prosecuting offenders. The problem is that THC tends to be stored in fat cells and continue to show on blood tests long after the ‘high’ effect has worn off for the user. Breath-based tests could eliminate some of these issues by testing for recent consumption paired with an upper legal limit.

Cannabix Technologies’ Chief Science Officer Dr. Raj Attariwala is working closely with Professor Richard Yost, Head of Analytical Chemistry at the University of Florida, to develop a scientific testing protocol. Additional input on the trial will be sought from consultants that are familiar with obtaining regulatory approvals for court certified devices from the Minister of Justice in Canada and the National Highway Transportation Bureau in the United States.

“When Cannabix first approached our lab with the goal of building a device that could detect trace amounts of THC through exhaled breath, we were excited to face the challenge,” said Dr. Yost. “We have been able to use our expertise and patent in FAIMS technology and build a device that achieves the required sensitivity and specificity but also will be a handheld portable device, similar to alcohol breathalyzers. We are extremely pleased and proud to be working on the design of a portable Cannabix Marijuana Breathalyzer that will be used by Law Enforcement to collect evidence of impaired driving and ensure safety on our roads as marijuana use becomes accepted in society and its use continues to grow.”

Looking Ahead

Cannabix Technologies Inc. is rapidly progressing with its THC breathalyzer. With ongoing legalization across the United States and Canada, the demand for such a device from law enforcement could be significant. Management’s experience in scientific testing, regulatory approvals, and law enforcement make the company a compelling opportunity in the space as it continues with development and prepares for further testing.

For more information, visit www.cannabixtechnologies.com or visit CannabisFN’s profile.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading